Author(s) :
Edvina E. Pîrvu1, Cristina E. Cocioabă1
- 1Medical Oncology Department, Colțea Clinical Hospital, Bucharest, Romania
Corresponding author: Edvina E. Pîrvu , Email: edvinapirvu@gmail.com
Publication History: Received - , Revised - , Accepted - , Published Online - .
Copyright: © The author(s). Published by Casa Cărții de Știință.
User License: Creative Commons Attribution – NonCommercial (CC BY-NC)
PDF
Share
Valoarea DOI extrasă din ACF este: 10.53011/JMRO.2022.02.09
Număr de citări pe Crossref pentru DOI 10.53011/JMRO.2022.02.09: 0
Verifică manual răspunsul API la acest link: http://api.crossref.org/works/10.53011/JMRO.2022.02.09
Abstract
Nivolumab, a fully human immunoglobulin G4 (IgG4) monoclonal antibody PD-1 immune checkpoint inhibitor and other immune checkpoint inhibitors are used to promote activation of anti-tumor immuno response in the fight against cancer. Recently published case reports raised awareness on a particular adverse effect of immunothrapy: reactivation of latent Mycobacterium tuberculosis infection. This case report describes a 67-year old Caucasian male who presented with concomitant tuberculosis infection of the pleura and pericardium with nivolumab therapy for non-small cell lung cancer. He received antituberculous treatment, with favorable evolution. With no available guidelines for the management of tuberculosis during PD-1/PD-L1 blockade, a high index of suspicion should exist when the evolution of the patient takes an unexpected turn. This approach should be applied especially in countries with a high incidence of tuberculosis.
